Clinical Trials Details

A221805 (Peripheral Neuropathy)

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Objective

Key eligibility: Open to Stage II or III colorectal cancer patients scheduled to receive oxaliplatin; no prior neurotoxic chemotherapy; no pre-existing (PN) neuropathy.

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms